Study of CD133KDEL Toxin in the Treatment for Solid Tumors

Summary

This is a single center, phase I dose escalation study designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of deimmunized CD133KDEL (dCD133KDEL), a ligand-directed, deimmunized pseudomonas toxin against CD133, in patients with advanced, previously treated, refractory solid tumors.

Timeline

Start

2018-12

Primary completion

2022-01

Completion

2022-01

Outcome

Outcome not reported

Stopped (Business): “Funding unavailable”

Drugs

Indications